Literature DB >> 11466369

Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.

M R Sarrias1, S Franchini, G Canziani, E Argyropoulos, W T Moore, A Sahu, J D Lambris.   

Abstract

The molecular mechanisms involved in the interaction of complement receptor 2 (CR2) with its natural ligands iC3b and C3d are still not well understood. In addition, studies regarding the binding site(s) of the receptor on C3 as well as the affinities of the C3 fragments for CR2 have produced contradictory results. In the present study, we have used surface plasmon resonance technology to study the interaction of CR2 with its ligands C3d, iC3b, and the EBV surface glycoprotein gp350/220. We measured the kinetics of binding of the receptor to its ligands, examined the influence of ionic contacts on these interactions, and assessed whether immobilized and soluble iC3b bound with similar kinetics to CR2. Our results indicate that 1) gp350 binding to CR2 follows a simple 1:1 interaction, whereas that of the C3 fragments is more complex and involves more than one intramolecular component; 2) kinetic differences exist between the binding of C3d and iC3b to CR2, which may be due to an additional binding site found on the C3c region of iC3b; and 3) iC3b binds to CR2 with different kinetics, depending on whether the iC3b is in solution or immobilized on the surface. These findings suggest that binding of CR2 to iC3b and C3d is more complex than previously thought.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466369     DOI: 10.4049/jimmunol.167.3.1490

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.

Authors:  Masha Fridkis-Hareli; Michael Storek; Eran Or; Richard Altman; Suresh Katti; Fang Sun; Tao Peng; Jeff Hunter; Krista Johnson; Yi Wang; Ante S Lundberg; Gaurav Mehta; Nirmal K Banda; V Michael Holers
Journal:  Mol Immunol       Date:  2018-12-01       Impact factor: 4.407

2.  Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization.

Authors:  Li-Xin Wang; Wei Xu; Qing-Dong Guan; Yi-Wei Chu; Ying Wang; Si-Dong Xiong
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

3.  High-potentiality preliminary selection criteria and transformation time-dependent factors analysis for establishing Epstein-Barr virus transformed human lymphoblastoid cell lines.

Authors:  I-C Chang; J-Y Wu; H-I Lu; H-W Ko; J-L Kuo; C-Y Wang; P-S Shen; S-M Hwang
Journal:  Cell Prolif       Date:  2006-12       Impact factor: 6.831

Review 4.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d.

Authors:  Nurit Haspel; Daniel Ricklin; Brian V Geisbrecht; Lydia E Kavraki; John D Lambris
Journal:  Protein Sci       Date:  2008-08-07       Impact factor: 6.725

6.  Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.

Authors:  James M Kovacs; Jonathan P Hannan; Elan Z Eisenmesser; V Michael Holers
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

7.  Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.

Authors:  Kendra A Young; Andrew P Herbert; Paul N Barlow; V Michael Holers; Jonathan P Hannan
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

8.  Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines.

Authors:  Raymond P Brinãs; Andreas Sundgren; Padmini Sahoo; Susan Morey; Kate Rittenhouse-Olson; Greg E Wilding; Wei Deng; Joseph J Barchi
Journal:  Bioconjug Chem       Date:  2012-07-31       Impact factor: 4.774

9.  A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family.

Authors:  Daniel Ricklin; Apostolia Tzekou; Brandon L Garcia; Michal Hammel; William J McWhorter; Georgia Sfyroera; You-Qiang Wu; V Michael Holers; Andrew P Herbert; Paul N Barlow; Brian V Geisbrecht; John D Lambris
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

10.  Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE).

Authors:  Rengasamy Asokan; Nirmal K Banda; Gerda Szakonyi; Xiaojiang S Chen; V Michael Holers
Journal:  Mol Immunol       Date:  2012-08-10       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.